Table 1.
Study group descriptions
| Study groups† | Mean creatinine clearance (range), ml min−1 | n | Exenatide dose, µg | Gender distribution, male : female | Age, mean±SD, years | Body weight±SD, kg | BMI, mean±SD, kg m−2 |
|---|---|---|---|---|---|---|---|
| Healthy (control) | 111 (83–156) | 8 | 10 | 3 : 5 | 46 ± 5.5 | 73.3 ± 10.9 | 25.7 ± 4.08 |
| Mild RI | 68 (60–78) | 8 | 10 | 5 : 3 | 56 ± 9.9 | 76.9 ± 13.3 | 25.5 ± 2.77 |
| Moderate RI | 45 (34–50) | 7 | 5 or 10‡ | 5 : 2 | 64 ± 9.6* | 76.1 ± 12.6 | 27.2 ± 3.02 |
| ESRD | N/A | 8 | 5 | 3 : 5 | 52 ± 18.3 | 64.1 ± 13.5 | 23.7 ± 3.29 |
*
P < 0.05, compared with normal renal function group. BMI, Body mass index; RI, renal impairment; ESRD, end-stage renal disease.
†
Inclusion criteria for study groups based on Cockcroft–Gault creatinine-clearance (CrCL): normal renal function: CrCL>80 ml min−1; Mild RI: CrCL 51–80 ml min−1; Moderate RI: CrCL 31–50 ml min−1; ESRD: haemodialysis for at least 1 month at screening.
‡
Five patients received 5 µg and two patients received 10 µg exenatide.